Global Leadership Team
Our executive team is comprised of senior leaders from accross the Company. Together, they form a forward-thinking, collaborative, multicultural group of leaders
Chairman and CEO Stallergenes Greer
Fereydoun Firouz is the Chairman and Chief Executive Officer of Stallergenes Greer. He has 27 years pharmaceutical industry and leadership experience.
More recently he was Managing Partner of Gurnet Point Capital, an investment firm focused in Life Science investments and Managing Director of Waypoint Capital Inc. Prior to this, he was President and CEO of EMD Serono, Inc. and Head of the Global Business Unit Fertility and Endocrinology franchise. He was also a member of the Executive Management Board of Merck Serono in Geneva. He is a past Board Member of the Pharmaceutical Research and Manufacturers of America (PhRMA), the Biotechnology Industry Organization (BIO), and the Massachusetts Biotech Council (MBC). Mr. Firouz is a Board Member at the John F. Kennedy Library Foundation and a Presidential Advisory Council member of the Berklee College of Music in Boston. He is also a Director of Bertarelli Partners Ltd., Capstan Ltd. and Rigger Ltd.
Chief Financial Officer
Matthias A. Vogt
Matthias A. Vogt joined Stallergenes Greer from Axalta Coating Systems, where he led the Finance and M&A functions in Europe.
Prior to that he was member of the Management Board and CFO of Merz Pharma Group in Frankfurt since July 2008. Before Merz, he was CFO of the global OTC business of Novartis, where he worked for 11 years in several Finance and CFO positions in Switzerland, Latin America and the US. After graduating with a degree in Industrial Engineering he worked as a Technical Trainee at Lürssen Werft in Bremen and as Research Associate at Harvard Business School. He holds a Ph.D. in Finance from Justus Liebig University in Germany.
General Counsel and Company Secretary
Devin Smith joined the company from EMD Serono, Inc., the biopharmaceutical division of Merck KGaA, Darmstadt, Germany.
At EMD Serono, Devin Smith led the North American legal department as Vice President and General Counsel.
Prior to EMD Serono, Devin Smith was an associate lawyer and then partner at the international law firm of Nixon Peabody LLP, where he represented emerging and established life science, information technology and manufacturing businesses.
Devin Smith received his law degree (cum laude) from Suffolk University Law School and a B.A. in political science from the University of North Carolina - Chapel Hill.
Executive Vice President, Head of Europe & International, President of Stallergenes SAS
Michele Antonelli has more than 20 years of international experience in the biopharmaceutical industry with extensive expertise in both manufacturing and commercial.
Michele Antonelli previously worked at UCB where he held roles of various responsibility and scope, most recently serving as Executive Vice President and Head of lmmunology Europe, overseeing the region’s commercial, medical, and market access activities.
Prior to joining UCB, Michele spent 16 years at Merck Serono, ultimately serving as Senior Vice President and Global Head of Biotech Manufacturing and Process Development.
Executive Vice President, Head of Americas
Tibor Nemes has more than 20 years of experience in the biotech and pharmaceutical industry in both Europe and in the United States with a proven track record of leadership in engineering, process development, quality assurance and the manufacturing of biologics, solids, and sterile dosage forms.
Tibor joined Stallergenes Greer in 2016 and served as Global Head of Technical Operations before taking over as Head of the Americas in May 2018.
Tibor previously spent eight years at Novartis where he held roles of increasing responsibility, most recently as the Global Operations Head, Tech Ops Manufacturing, Strategy and BDM&A where he headed Operations for Manufacturing Strategy and Business Development & Licensing within Global Technical Operations.
Prior to Novartis, Tibor held Engineering and Operations leadership roles at pharmaceutical and biotechnology companies including Novavax, Inc., Bristol-Myers Squibb Company, Elan Pharmaceuticals and Hypex, Inc.